Over the past two decades, there has been significant interest in intranasal oxytocin as an adjunctive therapy for various psychiatric disorders.77, 78, 79 However, recent meta-analyses in schizophrenia, including up to 10 RCTs, have not provided convincing evidence that intranasal oxytocin improves core schizophrenia symptoms.80 The gene discussed is OXT; the disease is schizophrenia.